Congress urges FDA to re-examine abortion pill safety amid disputed claims
H.Res. 803 — Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes. · Filed by John Rose (R-TN) · 11 cosponsors · Introduced Oct 10, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This is a non-binding resolution urging the FDA Director to re-examine the safety of medication abortion drugs (mifepristone and misoprostol) and release a public safety review. The resolution frames this request around claims that independent studies show complication rates 22 times higher than FDA reports, and expresses concern about expanded access policies under prior administrations. It does not change any law or FDA authority—it is a statement of congressional opinion.
Why we flagged it
This is a non-binding resolution expressing congressional opinion and urging executive action. It does not legislate, appropriate funds, or change law. Its functional character is political messaging framed as a call for regulatory review.
What the text implies
- If FDA complies with the reevaluation request, the resulting review could become a political flashpoint and may influence state-level abortion restrictions or litigation, even if the review confirms existing safety data.
- The resolution's citation of a 22x complication-rate claim without naming the study or methodology may amplify unverified claims into the legislative record, potentially influencing public perception and future regulatory decisions.
- A public safety review, if conducted, could be weaponized by either side of the abortion debate regardless of its findings, reducing public trust in FDA independence.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The resolution's stated goal—transparent safety review of a medication affecting millions—serves public interest in informed decision-making and regulatory accountability. However, the framing selectively emphasizes complication claims and pro-life concerns while omitting context about existing FDA approval processes, comparative safety data, or the medical consensus on medication abortion safety. Citizens benefit from transparency but may be misled by the resolution's one-sided presentation of
Named in the bill
Food and Drug Administration (FDA), mifepristone (medication abortion drug), misoprostol (medication abortion drug), House Committee on Energy and Commerce, Obama administration, Biden administration
Where it stands
11 cosponsors: 11 Republicans.
- Oct 10, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (2,832 characters) on Apr 3, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“Congress urges FDA to re-examine abortion pill safety amid disputed claims” QuorumCivic. https://share.quorumcivic.app/bill/119/hres803 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.